Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

(2012) E. Corse et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

(2010) Xingxing Zang et al.   MODERN PATHOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

(2009) K. S. Peggs et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE